Butyltolylquinuclidine: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

@@ Line 1: / Line 1: @@
+{{Short description|Stimulant drug}}
-{{drugbox
+{{Drugbox
-| verifiedrevid = 316412647
+| verifiedrevid = 424688456
-| IUPAC_name        = (2R,3S,4S)-2-butyl-3-''p''-tolylquinuclidine
+| IUPAC_name = (2R,3S,4S)-2-butyl-3-''p''-tolylquinuclidine
-| image             = Butyltolylquinuclidine.png
+| image = Butyltolylquinuclidine Structure.svg
-| CAS_number        =
+| alt = Skeletal formula of butyltolylquinuclidine
-| ATC_prefix        =
+| image2 = Butyltolylquinuclidine molecule ball.png
-| ATC_suffix        =
+| alt2 = Ball-and-stick model of the butyltolylquinuclidine molecule
-| PubChem           = 9903250
+| width2 = 200
-| DrugBank          =
-| C = 18 | H = 27 | N = 1
+<!--Clinical data-->
-| molecular_weight  = 257.414 g/mol
+| tradename =
-| smiles            = C3CC1CCN3C(CCCC)C1c(cc2)ccc2C
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
-| bioavailability   =
+| pregnancy_US = <!-- A / B            / C / D / X -->
-| protein_bound     =
+| pregnancy_category =
-| metabolism        =
+| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| elimination_half-life =
+| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| excretion         =
-| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
+| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| pregnancy_US      =  <!-- A / B            / C / D / X -->
+| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
+| legal_status = Legal
-| pregnancy_category=
-| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
+<!--Pharmacokinetic data-->
-| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
+| bioavailability =
-| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
+| protein_bound =
-| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
+| metabolism =
-| legal_status      = Legal
+| elimination_half-life =
-| routes_of_administration =
+| excretion =
+<!--Identifiers-->
+| CAS_number =  328047-48-9
+| ATC_prefix = none
+| ATC_suffix =
+| PubChem = 9903250
+| ChemSpiderID = 8013735
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| UNII = J5W6BTT4ZQ
+<!--Chemical data-->
+| C=18 | H=27 | N=1
+| smiles = C3CC1CCN3C(CCCC)C1c(cc2)ccc2C
+| StdInChI=1S/C18H27N/c1-3-4-5-17-18(15-8-6-14(2)7-9-15)16-10-12-19(17)13-11-16/h6-9,16-18H,3-5,10-13H2,1-2H3
+| StdInChIKey = QYIZEJQSBLRXJK-UHFFFAOYSA-N
 }}
-'''2-Butyl-3-(p-tolyl)quinuclidine''' ('''BTQ''') is a [[stimulant]] [[dopamine reuptake inhibitor|DRI]].<ref>{{Cite pmid|12614900}}</ref> It is one of a number of substituted [[quinuclidine]] derivatives developed as potential medications for the treatment of [[cocaine]] abuse,<ref>{{Cite pmid|12565962}}</ref> and produces similar effects to cocaine in animal studies, although milder and longer lasting.
+'''2-Butyl-3-(p-tolyl)quinuclidine''' ('''BTQ''') is a [[stimulant]] [[dopamine reuptake inhibitor|DRI]].<ref>{{cite journal | vauthors = Sakamuri S, Enyedy IJ, Zaman WA, Tella SR, Kozikowski AP, Flippen-Anderson JL, Farkas T, Johnson KM, Wang S | display-authors = 6 | title = 2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors | journal = Bioorganic & Medicinal Chemistry | volume = 11 | issue = 6 | pages = 1123–36 | date = March 2003 | pmid = 12614900 | doi = 10.1016/S0968-0896(02)00450-9 }}</ref> It is one of a number of substituted [[quinuclidine]] derivatives developed as potential medications for the treatment of [[cocaine]] abuse,<ref>{{cite journal | vauthors = Enyedy IJ, Sakamuri S, Zaman WA, Johnson KM, Wang S | title = Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors | journal = Bioorganic & Medicinal Chemistry Letters | volume = 13 | issue = 3 | pages = 513–7 | date = February 2003 | pmid = 12565962 | doi = 10.1016/S0960-894X(02)00943-5 }}</ref> and produces similar effects to cocaine in animal studies, although milder and longer-lasting.
+== See also ==
-{{pharm-stub}}
+* [[AL-1095]]
-==References==
+== References ==
 {{reflist}}
-{{DEFAULTSORT:Butyl-3-(p-tolyl)quinuclidine, 2-}}
 {{Stimulants}}
+{{Monoamine reuptake inhibitors}}
-{{Dopaminergics}}
+{{DEFAULTSORT:Butyl-3-(p-tolyl)quinuclidine, 2-}}
+[[Category:2-Benzylpiperidines]]
 [[Category:Stimulants]]
 [[Category:Dopamine reuptake inhibitors]]
 [[Category:Quinuclidines]]
+{{nervous-system-drug-stub}}